Comparison of clinical outcomes between Dresden and accelerated corneal cross-linking in cases of progressive keratoconus
Session Details
Session Title: Presented Poster Session: Cornea IV
Venue: Poster Village: Pod 3
First Author: : T.Kojima JAPAN
Co Author(s): : M. Morikawa Y. Yoshida T. Nakamura Y. Satoh K. Ichikawa
Abstract Details
Purpose:
To compare the clinical outcomes between the Dresden protocol and accelerated corneal crosslinking (CXL) in cases with progressive keratoconus.
Setting:
Nagoya Eye Clinic, Nagoya, Japan
Satoh Yuya Eye Clinic, Sendai, Japan
Methods:
Sixty-seven eyes of 56 Japanese patients with progressive keratoconus who underwent corneal crosslinking and were followed-up for 1 year were enrolled in this retrospective comparative study. The Dresden protocol involved application of riboflavin, then ultraviolet (UV) light (3 mW/cm2) irradiation for 30 minutes. Accelerated crosslinking comprised UV irradiation (KLX system, Avedro; 18 mW/cm2) for 5 minutes. Uncorrected distance visual acuity (UDVA), corrected distance visual acuity (CDVA), average keratometric power and cylinder (measured by TMS4, TOMEY), and postoperative complications were compared between the 2 groups. Friedman test was used for statistical analyses with p<0.05 indicating statistical significance.
Results:
The mean UDVA and CDVA in both groups significantly improved 1 year after surgery (UDVA: pDresden=0.007, pAccelerated CXL=0.023; CDVA: pDresden =0.027, pAccelerated CXL= 0.016).
The mean average K in both groups significantly decreased 1 year after surgery (Dresden: from 48.5±4.5D to 47.5±4.3D, p=0.037; accelerated CXL: from 49.5±5.9D to 47.7±4.7D, p=0.022). Corneal refractive cylinder and corneal endothelial cell densities in both groups were not significantly different before and 1 year after surgery. At the 1-year follow-up visit, 5 eyes in the Dresden group and 1 eye in the accelerated CXL group showed faint deep stromal opacity.
Conclusions:
The study revealed that the Dresden protocol and accelerated CXL have equivalent treatment effects in patients with progressive keratoconus.
Financial Disclosure:
receives consulting fees, retainer, or contract payments from a company producing, developing or supplying the product or procedure presented
